drugset / Trial / NCT06641908
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1
Recruiting
52 enrolled
EMD Serono Research & Development Institute, Inc.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · collab
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
Timeline
- Start
- 2024-11-08
- Primary completion
- 2027-04-16
- Completion
- 2027-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M3554 | Unknown | — | — |